Development of Specific Inhibitors of Parasitic Enzymes

寄生酶特异性抑制剂的开发

基本信息

  • 批准号:
    nhmrc : 102582
  • 负责人:
  • 金额:
    $ 13.3万
  • 依托单位:
  • 依托单位国家:
    澳大利亚
  • 项目类别:
    NHMRC Project Grants
  • 财政年份:
    2000
  • 资助国家:
    澳大利亚
  • 起止时间:
    2000-01-01 至 2002-12-31
  • 项目状态:
    已结题

项目摘要

Parasitic diseases such as malaria, schistosomiasis, filariasis, leishmaniasis, and american trypanosomiasis (Chaga?s disease) are a significant public health issue, especially in tropical and subtropical regions of the world. In children, they cause death or impaired growth and in adults debilitating chronic illness. These parasitic infections are increasingly being recognized as responsible for chronic illness in many industrialized countries as well. There are no vaccines currently available for the treatment of any of the human parasitic infections. In addition, the drugs that are currently used are becoming less effective because of the spread of drug resistant strains. Schistosomiasis, is the second most prevalent parasitic disease, after malaria, and is a leading cause of severe morbidity and death in many parts of the world. The disease is caused by flatworms or blood flukes, the eggs of which indirectly cause damage to the liver and spleen of infected individuals. These parasites feed on human red blood cells and use hemoglobin as their major food source. Our collaborative team (Brindley, Abbenante, Fairlie) has identified two enzymes that these flatworms need to use to eat red blood cells. This project aims to develop compounds that will stop these enzymes from functioning. These compounds will be tested to see whether they can cause the parasites to die of starvation. If successful these new compounds can be used as drugs to treat the disease and the general strategy can be applied to other blood-feeding parasites.
疟疾、血吸虫病、丝虫病、利什曼病和美洲锥虫病(白桦茸病)等寄生虫病是一个重大的公共卫生问题,特别是在世界热带和亚热带地区。在儿童中,它们会导致死亡或生长受损,在成人中则导致慢性疾病。人们越来越认识到这些寄生虫感染也是许多工业化国家慢性疾病的原因。目前尚无疫苗可用于治疗任何人类寄生虫感染。此外,由于耐药菌株的传播,目前使用的药物的效果越来越差。血吸虫病是仅次于疟疾的第二大流行寄生虫病,是世界许多地区严重发病和死亡的主要原因。该疾病是由扁虫或血吸虫引起的,其卵间接损害感染者的肝脏和脾脏。这些寄生虫以人类红细胞为食,并使用血红蛋白作为主要食物来源。我们的合作团队(Brindley、Abbenante、Fairlie)已经确定了这些扁虫需要用来吃红细胞的两种酶。该项目旨在开发能够阻止这些酶发挥作用的化合物。这些化合物将被测试,看看它们是否会导致寄生虫饿死。如果成功,这些新化合物可以用作治疗该疾病的药物,并且总体策略可以应用于其他吸血寄生虫。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John Abbenante其他文献

John Abbenante的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John Abbenante', 18)}}的其他基金

C3/C5 Convertase Inhibitors As A New Class Of Anti-Inflammatory Drugs
C3/C5 转化酶抑制剂作为一类新型抗炎药物
  • 批准号:
    nhmrc : 301178
  • 财政年份:
    2004
  • 资助金额:
    $ 13.3万
  • 项目类别:
    NHMRC Project Grants

相似国自然基金

花胶鱼类物种Species-specific PCR和Multiplex PCR鉴定体系研究
  • 批准号:
    31902373
  • 批准年份:
    2019
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Development of FRET system for screening of PAD-specific inhibitors from periodontopathogenic bacteria.
开发用于从牙周病原菌中筛选 PAD 特异性抑制剂的 FRET 系统。
  • 批准号:
    22KJ2324
  • 财政年份:
    2023
  • 资助金额:
    $ 13.3万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Research and development of autophagy-specific inhibitors
自噬特异性抑制剂的研发
  • 批准号:
    23K06024
  • 财政年份:
    2023
  • 资助金额:
    $ 13.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of RyR2-specific inhibitors and activators and their application as antiarrhythmic agents
RyR2特异性抑制剂和激活剂的开发及其作为抗心律失常药物的应用
  • 批准号:
    22K06652
  • 财政年份:
    2022
  • 资助金额:
    $ 13.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of ubiquitin-specific protease 8 (USP8) inhibitors
泛素特异性蛋白酶 8 (USP8) 抑制剂的开发
  • 批准号:
    10460124
  • 财政年份:
    2021
  • 资助金额:
    $ 13.3万
  • 项目类别:
Design and development of HDAC11-specific chemical inhibitors for disease treatments
用于疾病治疗的 HDAC11 特异性化学抑制剂的设计和开发
  • 批准号:
    10360661
  • 财政年份:
    2021
  • 资助金额:
    $ 13.3万
  • 项目类别:
Development of Novel Lung Cancer Therapy Using Tumor-Specific Angiogenesis Inhibitors and Drug Repositioning
使用肿瘤特异性血管生成抑制剂和药物重新定位开发新型肺癌疗法
  • 批准号:
    21H03019
  • 财政年份:
    2021
  • 资助金额:
    $ 13.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Design and development of HDAC11-specific chemical inhibitors for disease treatments
用于疾病治疗的 HDAC11 特异性化学抑制剂的设计和开发
  • 批准号:
    10205726
  • 财政年份:
    2021
  • 资助金额:
    $ 13.3万
  • 项目类别:
Development of Location-specific Sialidase Inhibitors
位置特异性唾液酸酶抑制剂的开发
  • 批准号:
    10359898
  • 财政年份:
    2021
  • 资助金额:
    $ 13.3万
  • 项目类别:
Development of ubiquitin-specific protease 8 (USP8) inhibitors
泛素特异性蛋白酶 8 (USP8) 抑制剂的开发
  • 批准号:
    10672213
  • 财政年份:
    2021
  • 资助金额:
    $ 13.3万
  • 项目类别:
Design and development of HDAC11-specific chemical inhibitors for disease treatments
用于疾病治疗的 HDAC11 特异性化学抑制剂的设计和开发
  • 批准号:
    10581571
  • 财政年份:
    2021
  • 资助金额:
    $ 13.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了